Association of Higher Daptomycin Dose ( ≥ 7 mg/kg) with Improved Survival in Patients with Methicillin‐Resistant Staphylococcus aureus Bacteremia

ConclusionTo our knowledge, this is the first comparative effectiveness study of daptomycin doses in patients with MRSA bacteremia. Survival benefits were observed with doses higher than the daptomycin label dose (≥7 mg/kg) for the treatment of MRSA bacteremia. These data suggest that higher doses than the daptomycin label dose may be preferred over the label dose for improving clinical outcomes in patients with MRSA bacteremia.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Tags: Original Research Article Source Type: research